Immunotherapy technology developer Actinium Pharmaceuticals will work with Astellas Pharma to develop new actinium-225 targeted radiotherapies.
Actinium's antibody warhead-enabling platform and selected targeting agents from Astellas will be used to develop radiotherapies based on actinium-225, which has potential as a cancer-killing radioisotope.